GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Update

4 Jan 2011 07:00

RNS Number : 8214Y
ViaLogy PLC
04 January 2011
 



 

 

VIALOGY PLC.

January 4th 2011

ViaLogy reports key advances in QuantumRD market acceptance

Pasadena, January 4, 2011. ViaLogy PLC (LSE:VIY) makes the following announcements as part of a continuing effort to keep shareholders as fully informed of its progress as is permitted by publicity rules imposed by the company's clients or business partners.

ViaLogy has successfully completed its technology demonstration project on an offshore prospect for a global non-US major exploration and production company. Results have been acknowledged by the client as beyond the scope of conventional seismic processing and analysis technology, and as a potentially unique tool in reducing exploration and production risk. The client's evaluation was carried out using rigorous global services industry standards. The work marks the first application of ViaLogy's technology for an undersea prospect, and reinforces QuantumRD's value proposition for both complex offshore and onshore prospects. A second project is now underway for the same firm, this one focused on a key onshore prospect. In both cases the exploration problems were presented to ViaLogy after conventional seismic analysis techniques had been applied extensively.

In another important development, ViaLogy reports advanced discussions with a leading non-US national oil company, following its preliminary evaluation of QuantumRD, to apply the technology to an offshore prospect for full operational analysis and de-risking of expensive wells. This firm is looking to disruptive technologies for reducing risks in new, deeper fields and non-conventional formations.

ViaLogy will figure prominently this month at Geo India 2011, India's leading annual hydrocarbon exploration and production industry gathering in New Delhi. Due to interest sparked by the company's technology and its successes in the field, ViaLogy CTO Dr. Sandeep Gulati will present an invited keynote address. In addition ViaLogy geophysicists will conduct a two-day workshop on QuantumRD technology as a fundamental advance in seismic interferometry, a focus area of India's geophysical community. Presenting the technology to scientists and industry professionals comes at the request of a number of large Asian firms, and gives ViaLogy a select outreach opportunity.

Finally, strategic partnership discussions have begun with a leading O&G services company, following exploration of links with a number of such firms. If successful such a partnership could offer a near term path to access extensive global markets.

CEO Robert Dean said, "These and related activities have been our focus for some months, and they are key milestones in our strategy to accelerate and win the acceptance of QuantumRD in global markets. I am pleased with our progress, and we are doing our best to keep shareholders informed within the limitations imposed on us. Interest in the technology has been intense with the large firms we have chosen to work with. In all cases, in order to prove the unique value of QuantumRD, we have been presented with their hardest problems, which in itself should be an accelerated proving ground for the technology in some of the world's toughest exploration environments."

Mr. Dean points out that the gestation period from enquiry to technology acceptance takes considerably longer when dealing with supermajors and global oil exploration companies. "These complex businesses have techniques and processes already in place on which they base very large capital expenditure decisions," he said. "What we bring them in QuantumRD is a powerful risk reduction tool that complements and can be integrated with existing practices. Gaining user acceptance as a standard part of their operations is what takes time, and why they typically insist on demonstration projects and extended technical discussions."

Ends

For further information contact: 

ViaLogy

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy / Catherine Leftley, Corporate Finance +44 (0) 20-7107-8000

Katie Ratner / Jeremy Stephenson, Corporate Broking +44 (0) 20-7107-8000

About ViaLogy:

ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery. ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magneto telluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBRGDBBUGBGBX
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.